慢性肾脏病不同病因间的蛋白质谱及相关生物学通路:来自DAPA-CKD试验的新见解
本研究基于DAPA-CKD试验,对2485例基线血浆样本用Olink Explore分析2926种蛋白,比较糖尿病肾脏病(DKD)、肾小球肾炎(GN)和高血压肾病间的蛋白谱差异。DKD中PLXNB2、VAP-1和KIM-1较高,GN中nephrin较低而RAGE和HS6ST2较高,高血压肾病中epiregulin较高,表明白细胞介素-6为DKD上游调控因子。
要点
- DKD患者PLXNB2、VAP-1和KIM-1较非DKD升高,提示免疫激活、氧化应激和肾小管损伤。
- GN患者nephrin较其他病因降低,RAGE和HS6ST2升高,提示糖萼破坏和炎症。
- 高血压肾病患者epiregulin较其他CKD病因升高。
核心结论
- 本研究揭示了DKD、GN和高血压肾病患者间存在不同的蛋白质组差异,这些发现可能有助于阐明CKD病理生理的异质性分子表型。
研究设计与样本
- 基于DAPA-CKD试验的蛋白质组学生物标志物分析,纳入伴或不伴2型糖尿病、估算肾小球滤过率25-75 ml/min/1.73 m2且尿白蛋白与肌酐比值200-5000 mg/g的成人。
- 4304例随机化参与者中2485例(57.7%)有基线血浆蛋白质组数据,用Olink Explore分析2926种蛋白。
- 采用线性模型将每种CKD病因与其他病因比较,鉴定与DKD、GN和高血压肾病相关的蛋白。
主要发现
- 与无DKD患者相比,DKD患者PLXNB2较高(log2倍数差异0.34,P < .001)、VAP-1较高(log2倍数差异0.34,P < .001)、KIM-1较高(log2倍数差异0.79,P < .001)。
- 基于这些分子通路,白细胞介素-6被鉴定为DKD的上游调控因子。
- 在肾脏精准医学项目外部数据库中,DKD较非DKD的PLXNB2和VAP-1亦升高(log2倍数差异分别为0.41和0.42)。
- GN中nephrin较低(log2倍数差异-0.27,P < .001),RAGE较高(log2倍数差异0.28,P < .001),HS6ST2较高(log2倍数差异0.2,P < .05)。
- 高血压肾病中epiregulin较其他CKD病因升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) aetiologies to study its underlying molecular heterogeneity. METHODS: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an estimated glomerular filtration rate of 25-75 ml/min/1.73 m2 and a urine albumin:creatinine ratio of 200-5000 mg/g. A total of 2926 proteins were analysed by Olink Explore in plasma samples collected at baseline. Proteins associated with diabetic kidney disease (DKD), glomerulonephritis (GN) and hypertensive nephropathy were identified using linear models to compare each CKD aetiology against the others. RESULTS: Of 4304 randomized participants, baseline plasma proteomic profiles were available for 2485 participants (57.7%). Compared with patients without DKD, those with DKD had higher plexin B2 (PLXNB2; log2 fold difference 0.34, P < .001), vascular adhesion protein-1 (VAP-1; log2 fold difference 0.34, P < .001) and kidney injury molecule-1 (KIM-1; log2 fold difference 0.79, P < .001), suggesting involvement of immune activation, oxidative stress and tubular damage. Based on these molecular pathways, interleukin-6 was identified as an upstream regulator in DKD. In an external database of the Kidney Precision Medicine Project, PLXNB2 and VAP-1 were also elevated in DKD compared with non-DKD (log2 fold difference 0.41 and 0.42, respectively). In GN, levels of nephrin, a key slit diaphragm protein, were lower (log2 fold difference -0.27, P < .001). Furthermore, receptor for advanced glycation end products (log2 fold difference 0.28, P < .001) and heparan sulphate 6-O-sulfotransferase 2 (log2 fold difference 0.2, P < .05) were higher, suggesting glycocalyx disruption and inflammation. In hypertensive nephropathy, epiregulin, a member of the epidermal growth factor family, was higher compared with other CKD aetiologies. CONCLUSION: Our study highlights distinct proteomic differences in patients with DKD, GN and hypertensive nephropathy. These findings may aid in unravelling the heterogeneous underlying molecular phenotype of CKD pathophysiology.
引用
- de la Rambelje MA, Beldhuis IE, Heerspink HJL, et al. Protein profiles and associated biological pathways among different aetiologies of chronic kidney disease: new insights from DAPA-CKD. Nephrol Dial Transplant. 2026. PMID: 40920470. doi:10.1093/ndt/gfaf180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。